AN2 Therapeutics (ANTX) CFO granted stock options and RSUs

Rhea-AI Filing Summary

Day Lucy reported acquisition or exercise transactions in this Form 4 filing.

AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported equity awards consisting of a stock option for 77,000 shares and a grant of 38,000 shares of common stock on February 20, 2026. The common stock amount represents restricted stock units that vest 1/4 annually over four years from January 1, 2026, subject to continued service. The option vests 1/48 monthly over four years from the same date on a continued-service basis. Her common stock holdings total 118,363 shares, reflecting prior RSU grants of 27,500 and 46,500 units with annual vesting from January 1, 2024 and January 1, 2025, and a 5,000-share purchase under the 2022 Employee Stock Purchase Plan on March 31, 2025.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Day Lucy

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	77,000	$0.00	--
Grant/Award	Common Stock	38,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 77,000 shares (Direct); Common Stock — 118,363 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 46,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Day Lucy

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		A		38,000(1)	A	$0	118,363(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.04	02/20/2026		A			77,000	(4)	02/19/2036	Common Stock	77,000	$0	77,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

2. Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 46,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.

3. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025.

4. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Remarks:

Exhibits:

	/s/ Lucy Day	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANTX CFO Lucy Day report on this Form 4?

Lucy Day reported receiving a stock option for 77,000 shares and a grant of 38,000 shares of common stock. Both awards were dated February 20, 2026 and are subject to multi‑year vesting tied to her continued service with AN2 Therapeutics.

How do Lucy Day’s new ANTX restricted stock units vest?

The 38,000 restricted stock units vest 1/4 each year over four years starting January 1, 2026. Vesting continues only if Lucy Day remains in continuous service with AN2 Therapeutics through each applicable annual vesting date.

What are the vesting terms of Lucy Day’s new ANTX stock option grant?

The 77,000-share stock option vests in equal monthly installments of 1/48 over four years from January 1, 2026. Each monthly vesting tranche requires Lucy Day’s continuous service with AN2 Therapeutics through the applicable vesting date.

What prior ANTX RSU awards does Lucy Day hold in addition to this grant?

Lucy Day’s holdings include 27,500 RSUs vesting 1/4 annually from January 1, 2024 and 46,500 RSUs vesting 1/4 annually from January 1, 2025. Each RSU award remains subject to her continuous service through the relevant vesting dates.

How many ANTX common shares does Lucy Day own after these transactions?

Following the reported equity awards, Lucy Day holds 118,363 shares of AN2 Therapeutics common stock. This total reflects her RSU-related holdings plus a purchase of 5,000 shares under the 2022 Employee Stock Purchase Plan on March 31, 2025.

Was any ANTX stock bought or sold on the market in this Form 4?

The Form 4 shows grant or award acquisitions, not open-market trades. Reported transactions include a stock option grant and restricted stock unit awards, along with a prior 5,000-share purchase under the 2022 Employee Stock Purchase Plan referenced in a footnote.